LYONS GARY A sold $633K of TVTX
LYONS GARY A sold 10,000 shares of Travere Therapeutics, Inc. (TVTX) at an average of $63.28 ($62.53–$64.16, $0.63M total) across 5 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh data on insider holdings, useful for short-term sentiment analysis.
Market read
Direct insider sale may influence TVTX's stock price modestly; broader market impact minimal.
What to watch
Sale executed under pre-arranged 10b5-1 plan, reducing informational asymmetry.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources of insider activity.
Ticker impact
Director Gary Lyons sold approximately $633K of TVTX shares via a 10b5-1 plan, reducing his holding to 61,500 shares.
Modest downward pressure in near term.
Insider sales by a director can be interpreted as lack of confidence, but size is modest relative to market cap.
Market effects
May slightly affect biotech sector sentiment if similar insider sales occur.
Limited to US biotech investors.
Low global relevance.
Counterpoint
Director may be diversifying portfolio; sale does not reflect company fundamentals.
Key entities
- CompanyTravere Therapeutics, Inc.
Biopharmaceutical company developing treatments for rare diseases.
- InsiderGary Lyons
Director of Travere Therapeutics.
